Accumulating evidence suggests that a high tumour burden has a negative effect on
anticancer immunity. The concept of tumour burden, simply defined as the total amount of …

Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …

Continuous revision of the histologic and stage-wise classification of lung cancer by the
World Health Organization (WHO) provides the foundation for therapeutic advances by …

Non-small cell lung cancer is one leading cause of death worldwide, and patients would
greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged …

Immunotherapy has been one of the great advances in the recent years for the treatment of
advanced tumors, with nonsmall-cell lung cancer (NSCLC) being one of the cancers that …

Non-small cell lung cancer (NSCLC) is one of the most threatening malignancies to human
health and life. In most cases, patients with NSCLC are already at an advanced stage when …

The treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the
advent of immune checkpoint inhibitors (ICIs). Despite encouraging results, their efficacy …

Lung cancer is the leading cause of cancer morbidity and mortality worldwide and early
diagnosis is crucial for the management and treatment of this disease. Non-invasive means …

In recent years, the evolution of treatments has made it possible to significantly improve the
outcomes of patients with non-small cell lung cancer (NSCLC). In particular, while molecular …

Simple Summary Although immunotherapy has dramatically revolutionized non-small cell
lung cancer (NSCLC) treatment, not all the patients will benefit from this innovative therapy …